The FCF Healthcare & Life Sciences Venture Capital Monitor – USA is a monthly overview of financing trends in the venture capital sector, with a focus on U.S. healthcare and life sciences companies.
Total Healthcare & Life Sciences funding reached EUR 26,262m (+4% vs. 2025)
Biotech/Pharma received 43% of the total investment volume (EUR 11,235m), with oncology being the leading indication (30%)
In August, Sail Biomedicines secured the highest transaction volume with EUR 529m, followed by LifeMine with EUR 164m and Cityblock with EUR 101m
Boston Scientific (United States) is the most active investor (by deal volume in 2026), followed by General Catalyst (United States) and Jonson & Johnson JJDC (United States)
To read the full report, click here.